I am thinking we should collate a few questions that should be directed to the board at the upcoming AGM:
I'll start:
1: How many of the 650-odd global MSC trials has Cynata approached about its Cymerus technology?
2: How many large pharmacy firms has Cynata presented to in the last 2 years?
3: What is the current state of play with the MOU with Cellularity?
4: How many large financial institutions have approached Cynata after one of its many company presentations at events like the recent Rodman & Renshaw Investor Conference?
5: Can the board provide a detailed update on the Licencing Model strategy we are told we are pursuing.
Questions for the Board at the AGM
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $45.80M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 25.5¢ | 25.5¢ | $313 | 1.229K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 22209 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 36715 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |